BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

955 related articles for article (PubMed ID: 29935011)

  • 21. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.
    Ahn HY; Chung YJ; Kim BS; Kang KH; Seok JW; Kim HS; Park SJ; Cho BY
    Surgery; 2014 Apr; 155(4):689-95. PubMed ID: 24612623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study.
    Espiritu GAM; Malana JT; Dumasis AJGV; Ang DC
    J Glob Oncol; 2019 Jan; 5():1-6. PubMed ID: 30694737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
    Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
    Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
    Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
    Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
    Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.
    Ahn D; Park JS; Sohn JH; Kim JH; Park SK; Seo AN; Park JY
    Auris Nasus Larynx; 2012 Apr; 39(2):198-203. PubMed ID: 21862261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
    Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
    Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating US-guided FNAB, BRAF
    Ma N; Tian HY; Yu ZY; Zhu X; Zhao DW
    Eur Arch Otorhinolaryngol; 2023 Dec; 280(12):5565-5574. PubMed ID: 37540271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
    Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
    Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Analysis of BRAF
    Dong SY; Chen J; Xia EJ; Lin RX; Du HY; Wang OC; Zhang XH; Hao RT
    Am Surg; 2020 May; 86(5):450-457. PubMed ID: 32684022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
    [No Abstract]   [Full Text] [Related]  

  • 40. High TPOAb Levels (>1300 IU/mL) Indicate Multifocal PTC in Hashimoto's Thyroiditis Patients and Support Total Thyroidectomy.
    Dong S; Xia Q; Wu YJ
    Otolaryngol Head Neck Surg; 2015 Jul; 153(1):20-6. PubMed ID: 25917667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.